Status:
COMPLETED
Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland
Lead Sponsor:
Pirkko-Liisa Kellokumpu-Lehtinen
Collaborating Sponsors:
University of Turku
Oulu University Hospital
Conditions:
Neoplasms
Renal Cell Carcinoma
Eligibility:
All Genders
18-85 years
Brief Summary
Patient receiving sunitinib according the clinician's independent decision as first-line treatment of advanced renal cell carcinoma (RCC) will be asked for informed consent. Treatment with sunitinib w...
Eligibility Criteria
Inclusion
- Clinically indicated first-line sunitinib treatment for advanced RCC.
- Informed consent obtained.
Exclusion
- Unable to complete HRQoL forms.
- Not consenting to collecting register data.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00980213
Start Date
September 1 2009
End Date
December 1 2013
Last Update
February 6 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Kuopio University Hospital
Kuopio, Finland
2
Oulu Univeristy Hospital
Oulu, Finland
3
Tampere University Hospital
Tampere, Finland, Fi-33521
4
Turku University Hospital
Turku, Finland, Fi-20520